Profile data is unavailable for this security.
About the company
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
- Revenue in USD (TTM)28.59m
- Net income in USD-25.52m
- Incorporated1999
- Employees148.00
- LocationGenfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
- Phone+33 320164000
- Fax+33 320164001
- Websitehttps://www.genfit.fr/
More ▼
Mergers & acquisitions
| Acquired company | GNFT:PAR since announced | Transaction value |
|---|---|---|
| Versantis AG | -4.33% | 108.85m |
Data delayed at least 15 minutes, as of Jun 02 2023 12:03 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADC Therapeutics SA | 182.40m | -198.57m | 191.93m | 317.00 | -- | 5.09 | -- | 1.05 | -2.52 | -2.52 | 2.30 | 0.4673 | 0.3476 | 0.1423 | 7.18 | 575,400.60 | -37.84 | -47.88 | -44.24 | -54.34 | 98.83 | -- | -108.86 | -352.48 | 4.46 | -5.59 | 0.9001 | -- | 518.89 | 158.94 | 32.27 | -- | -6.15 | -- |
| AC Immune SA | 4.35m | -76.68m | 192.33m | 126.00 | -- | 1.14 | -- | 44.25 | -0.9152 | -0.9152 | 0.0519 | 2.02 | 0.0195 | -- | 21.27 | 34,497.03 | -34.31 | -18.28 | -36.35 | -19.56 | -- | -- | -1,764.17 | -154.12 | -- | -- | 0.0171 | -- | -- | -27.94 | 3.06 | -- | -7.22 | -- |
| Aadi Bioscience Inc | 18.78m | -61.88m | 193.05m | 80.00 | -- | 1.32 | -- | 10.28 | -2.64 | -2.64 | 0.7824 | 5.97 | 0.12 | 0.8415 | 4.54 | 237,670.90 | -39.54 | -50.93 | -43.62 | -56.01 | 91.03 | -- | -329.56 | -405.07 | 9.08 | -- | 0.00 | -- | 1,258.57 | -- | 45.03 | -- | 118.57 | -- |
| Ocean Biomedical Inc | 0.00 | -958.42k | 194.55m | 9.00 | -- | 0.7253 | -- | -- | -0.0725 | -0.0725 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -0.873 | -- | -0.888 | -- | -- | -- | -- | -- | -- | -- | 0.0202 | -- | -- | -- | -69.90 | -- | -- | -- |
| XOMA Corp | 3.36m | -30.11m | 194.95m | 12.00 | -- | 1.70 | -- | 58.07 | -2.63 | -2.63 | 0.2933 | 9.99 | 0.0229 | -- | 216.58 | 279,750.00 | -16.83 | -0.6127 | -17.93 | -0.6706 | -- | -- | -733.90 | -3.43 | -- | -- | 0.00 | -- | -84.21 | -35.19 | -383.33 | -- | 352.92 | -- |
| Zomedica Corp | 20.66m | -19.46m | 195.01m | 85.00 | -- | 0.7413 | -- | 9.44 | -0.0199 | -0.0199 | 0.0211 | 0.2684 | 0.0741 | 1.87 | 17.78 | 243,070.60 | -6.98 | -17.78 | -7.14 | -18.33 | 71.27 | -- | -94.20 | -384.78 | 14.82 | -- | 0.006 | -- | 358.01 | -- | 7.44 | -- | 74.64 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -30.97m | 196.98m | 21.00 | -- | 1.99 | -- | -- | -0.2119 | -0.2119 | 0.00 | 0.6232 | 0.00 | -- | -- | 0.00 | -26.70 | -31.66 | -28.08 | -33.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.28 | -- | -- | -- |
| Poseida Therapeutics Inc | 139.40m | -44.79m | 197.85m | 343.00 | -- | 1.26 | -- | 1.42 | -0.6054 | -0.6054 | 1.79 | 1.82 | 0.4963 | -- | -- | 443,949.00 | -15.95 | -44.02 | -19.09 | -50.94 | -- | -- | -32.13 | -278.04 | -- | -5.81 | 0.2702 | -- | 317.73 | 112.88 | 48.79 | -- | 81.18 | -- |
| Kinnate Biopharma Inc | 0.00 | -122.31m | 200.26m | 94.00 | -- | 0.8989 | -- | -- | -2.75 | -2.75 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -41.29 | -- | -46.53 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.53 | -- | -- | -- |
| Genfit SA (ADR) | 28.59m | -25.52m | 200.27m | 148.00 | -- | 2.03 | -- | 7.01 | -0.5138 | -0.5138 | 0.5755 | 2.04 | 0.1069 | 531.00 | 16.38 | 193,160.30 | -9.54 | -- | -12.01 | -- | 92.00 | -- | -89.29 | -- | 4.02 | -- | 0.4433 | -- | -68.96 | -- | -135.27 | -- | -- | -- |
| Kezar Life Sciences Inc | 0.00 | -74.41m | 201.29m | 84.00 | -- | 0.7797 | -- | -- | -1.06 | -1.06 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -27.76 | -29.68 | -28.87 | -30.93 | -- | -- | -- | -- | -- | -- | 0.0377 | -- | -- | -- | -24.91 | -- | 32.32 | -- |
| Gracell Biotechnologies Inc (ADR) | 0.00 | -85.64m | 201.79m | 314.00 | -- | 1.04 | -- | -- | -1.27 | -1.27 | 0.00 | 2.86 | 0.00 | -- | -- | 0.00 | -32.69 | -- | -36.37 | -- | -- | -- | -- | -- | -- | -- | 0.1063 | -- | -100.00 | -- | -33.89 | -- | -- | -- |
| Akebia Therapeutics Inc | 271.03m | -56.36m | 202.66m | 204.00 | -- | -- | -- | 0.7478 | -0.3112 | -0.3112 | 1.46 | -0.0772 | 0.6674 | 1.33 | 6.58 | 1,328,578.00 | -13.88 | -35.87 | -23.71 | -52.65 | 85.26 | 69.23 | -20.79 | -87.94 | 1.21 | -2.42 | 1.40 | -- | 37.00 | 10.06 | 67.27 | -- | -41.20 | -- |
| Eyepoint Pharmaceuticals Inc | 39.79m | -102.44m | 204.44m | 144.00 | -- | 2.61 | -- | 5.14 | -2.74 | -2.74 | 1.06 | 2.29 | 0.1994 | 1.94 | 2.65 | 276,340.30 | -51.33 | -- | -60.27 | -- | 81.93 | -- | -257.44 | -- | 5.21 | -- | 0.3066 | -- | 12.09 | -- | -75.04 | -- | -- | -- |
| Altimmune Inc | -79.00k | -85.36m | 204.56m | 52.00 | -- | 1.22 | -- | -- | -1.76 | -1.76 | -0.0016 | 3.40 | -0.0004 | -- | -- | -1,519.23 | -43.47 | -41.05 | -47.60 | -44.12 | -- | -- | -- | -1,013.75 | -- | -- | 0.00 | -- | -101.54 | -- | 12.75 | -- | -5.40 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -45.03m | 205.13m | 39.00 | -- | 1.15 | -- | -- | -1.11 | -1.11 | 0.00 | 4.37 | 0.00 | -- | -- | 0.00 | -22.08 | -- | -22.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 57.40 | -- | -- | -- |
Data as of Jun 01 2023. Currency figures normalised to Genfit SA's reporting currency: US Dollar USD
4.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 20 Apr 2023 | 1.21m | 2.44% |
| Adage Capital Management LPas of 31 Mar 2023 | 516.06k | 1.04% |
| DAFNA Capital Management LLCas of 31 Mar 2023 | 197.94k | 0.40% |
| Millennium Management LLCas of 31 Mar 2023 | 57.78k | 0.12% |
| Morgan Stanley & Co. International Plcas of 31 Mar 2023 | 43.23k | 0.09% |
| Ikarian Capital LLCas of 31 Mar 2023 | 32.79k | 0.07% |
| Optiver US LLCas of 31 Mar 2023 | 26.84k | 0.05% |
| Envestnet Asset Management, Inc.as of 31 Dec 2022 | 26.55k | 0.05% |
| O'Shaughnessy Asset Management LLCas of 31 Mar 2023 | 24.46k | 0.05% |
| Two Sigma Investments LPas of 31 Mar 2023 | 21.37k | 0.04% |
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
